Investment Thesis
ALX Oncology is a pre-revenue biotech company with zero commercial sales and negative operating cash flow of -$18.6M, indicating heavy R&D investment burn with no near-term profitability path. While the company maintains a strong balance sheet with $151.3M equity, low debt (0.06x), and $32.3M cash, the fundamental financial model is unsustainable without either successful drug commercialization or significant capital raises; current runway at this burn rate is approximately 18-24 months.
Strengths
- Strong balance sheet with $151.3M stockholders' equity and minimal leverage (0.06x debt-to-equity)
- Excellent liquidity position (7.21x current ratio) with $32.3M cash buffer
- Improving cash burn efficiency (EPS improving 26.4% YoY despite losses)
Risks
- Zero revenue and zero path to profitability absent successful drug development and commercialization
- Negative free cash flow of -$18.7M with 18-24 month cash runway at current burn rate, necessitating additional financing
- Extreme execution risk dependent on success of pre-clinical/clinical drug candidates with no near-term revenue catalysts
Key Metrics to Watch
- Cash burn rate and months of runway remaining
- Clinical trial progress and FDA milestone achievements for pipeline candidates
- Capital raise activities and financing needs to extend runway
Financial Metrics
Revenue
0.0
Net Income
-17.9M
EPS (Diluted)
$-0.17
Free Cash Flow
-18.7M
Total Assets
178.3M
Cash
32.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-11.8%
ROA
-10.1%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
7.21x
Quick Ratio
7.21x
Debt/Equity
0.06x
Debt/Assets
15.1%
Interest Coverage
-57.30x
Long-term Debt
8.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:32:42.035371 |
Data as of: 2026-03-31 |
Powered by Claude AI